

[Polymyxin B \(injection\)](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.2. Antibacterials 6.2.3. Reserve group antibiotics](#)

ATC codes: [J01XB02](#)

EMLc

Indication

Carbapenem resistant Enterobacterales ICD11 code: [MG50.C0](#)

INN

Polymyxin B

Medicine type

Chemical agent

Antibiotic groups

[RESERVE](#)

List type

Complementary

Formulations

Parenteral > General injections > IV: 500000 IU in vial powder for injection (equivalent to 50 mg polymyxin B base)

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Polymyxin B \(injection\)](#)

DrugBank

[Polymyxin b \(Polymyxin B Sulfate\)](#)

Summary of evidence and Expert Committee recommendations



In consideration of the review of the age appropriateness of formulations of medicines on the EMLc, and the comparison report of the EML versus EMLc, the Expert Committee recommended changes to the EMLc for addition of new, age-appropriate formulations and strengths of existing essential medicines, deletion of unavailable or age-inappropriate formulations and strengths, and other listing modifications as proposed in the application. The Committee also endorsed the proposals for further review of the public health relevance and evidence for specific medicines for use in children for potential future consideration for inclusion on the EMLc. The Committee noted and welcomed the ongoing review being coordinated by the Secretariat for the remaining sections of the EMLc for consideration by the 2025 Expert Committee. As a result of the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listing for polymyxin B on the EML and EMLc be amended to include also the equivalent strength in mg of polymyxin B base.